The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Abstract Details
|
Activity Number:
|
500
|
|
Type:
|
Topic Contributed
|
|
Date/Time:
|
Wednesday, August 3, 2011 : 10:30 AM to 12:20 PM
|
|
Sponsor:
|
Biopharmaceutical Section
|
| Abstract - #301906 |
|
Title:
|
A Review of Covariate-Adjusted Endpoint Analysis
|
|
Author(s):
|
Zhen Zhang*+
|
|
Companies:
|
Abbott Vascular
|
|
Address:
|
3200 Lakeside Drive, Santa Clara, CA, 95054,
|
|
Keywords:
|
randomized clinical trial ;
covariate adjustment ;
endpoint ;
variable selection
|
|
Abstract:
|
In randomized clinical trials (RCT), it is often believed that the whole randomization process will eliminate all biases and provide an ideal situation for unconditional test of the treatment effect. However, recent literatures suggested that even in RCTs, covariate-adjusted endpoint analysis (CAEA), when used appropriately, can improve the accuracy of the estimate of the effect size and therefore boost power of the endpoint analysis. In our work, we first provide a thorough review of recent developments in CAEA. Next, through extensive and carefully designed simulations, we will demonstrate advantages as well as disadvantages associated CAEA. Last, we will illustrate through examples on how to incorporate CAEA in trial design.
|
The address information is for the authors that have a + after their name.
Authors who are presenting talks have a * after their name.
Back to the full JSM 2011 program
|
2011 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Continuing Education program, please contact the Education Department.